News & Events

• March 18, 2020
  

  C-Path and Lundbeck Announce a Data Sharing Collaboration to Enable Development of Advanced Drug Development Tools in Alzheimer’s Disease

  C-Path and H. Lundbeck A/S are proud to announce that they will work together to significantly improve the scientific community’s insight in Alzheimer’s disease through Lundbeck’s contribution of a unique set of clinical trial data from more than 2,500 AD patients to the Critical Path for Alzheimer’s Disease consortium’s integrated database for qualified researchers across the globe to access.

• March 17, 2020
  

  C-Path to Lead Multi-Stakeholder Engagement on FDA’s Proposed Novel Framework to Enhance the Pediatric Medical Device Ecosystem

  C-Path today announced it has been awarded a grant to conduct stakeholder engagement to garner insights, feedback and refinement of the FDA Center for Devices and Radiological Health’s proposed framework to enhance the pediatric medical device ecosystem and to develop a strategic plan for implementation.

• March 12, 2020
  

  C-Path Appoints Dr. Klaus Romero as Chief Science Officer

  The Critical Path Institute (C-Path) today announced the appointment of Klaus Romero, M.D., M.S., F.C.P., as its new Chief Science Officer (CSO) effective April 1, 2020. Dr. Romero, a clinical pharmacologist and epidemiologist with more than 17 years combined experience in academic and pharmaceutical clinical research, translational sciences, pharmacometrics, modeling and simulation and pharmacoepidemiology, has been with C-Path since December 2007. His most recent role has been as Executive Director of Clinical Pharmacology and Quantitative Medicine. He will continue in dual roles as CSO and head of the Quantitative Medicine Program.

• March 12, 2020
  

  C-Path Selects Experienced Neuroscientist to Lead Alzheimer’s Consortium

  The Critical Path Institute (C-Path) today announced it has named Sudhir Sivakumaran, Ph.D., as Executive Director of its Critical Path for Alzheimer’s Disease (CPAD) consortium effective immediately. Dr. Sivakumaran, a neuroscientist and research and development professional, has nearly 20 years combined experience in academic, pre-clinical and early clinical research and development, phase 1 and phase 2 clinical study design, data analysis and diligence and business development. He has been with C-Path since July 2019 as Associate Director for CPAD.

• January 29, 2020
  

  ERA4TB, an International Consortium to Accelerate the Development of Comprehensive Treatments Against Tuberculosis

  C-Path, Ltd. and more than 30 partners from 13 countries participate in the ERA4TB project.

  The ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative dedicated to the development of drugs against tuberculosis. With a team of more than thirty organizations and a budget of over 200 million euros ERA4TB will focus on developing a new, improved tuberculosis treatment. The partners will share their expertise, knowledge and resources to rapidly progress new candidate drugs into clinical trials.